NCT06087978

Study of RPT193 in Healthy Adult Male Subjects

A Phase 1, Open-Label Study to Characterize the Absorption, Metabolism, Excretion (ADME), and Mass Balance of a Single Oral Dose of [14C]-RPT193 in Healthy Adult Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: RAPT Therapeutics, Inc. · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.

Detailed description

A study of RPT193 in healthy volunteers to evaluate the route(s) of elimination and overall mass balance of RPT193 in urine and feces

Conditions

• Healthy Male Subjects

Interventions

Type	Name	Description
DRUG	14C RPT193	Radiolabelled RPT193

Timeline

• Start date: 2023-07-05
• Primary completion: 2023-10-12
• Completion: 2023-10-12
• First posted: 2023-10-18
• Last updated: 2023-11-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study